The effects of a prebiotic supplement on exercise induced asthma and markers of airway inflammatio

Completed

• Conditions: Exercise induced asthma; Respiratory; Asthma

• Registration Number: ISRCTN15022880
• Lead Sponsor: ottingham Trent University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2014-03-03
• Study Start: 2016-01-06
• Last Update Posted: 26 March 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Body mass index (BMI) 20-25 KG.M-2
2. Physically active 3 or more times a week , with each exercise session lasting at least 45 min
3. Non-smoker
4. Non-vegetarian or vegan
5. Asthma sufferers must have own clinically prescribed medication
6. Asthma sufferers must have a GP diagnosis

Exclusion Criteria

1. Predicted forced expiratory volume in 1 second (FEV1) less than 65%
2. Previously diagnosed with COPD, emphysema, chronic bronchitis or similar respiratory illness
3. Previously admitted to hospital for asthma or other breathing difficulties
4. Asthma exacerbation within the last month (Course of steroids, or hospital visit)
5. History of heart failure, pulmonary hypertension, embolism, or other pulmonary heart disease
6. History of recurrent chest infections
7. Smoker
8. Acute infection within the last four weeks
9. Major operation within the past four months
10. Have a history of taking ?-3 PUFA supplements or supplements with antioxidants above recommended intake, or consume more than three fatty fish meals per week
11. Take a daily dose of aspirin or other NSAIDs
12. Currently taking a daily dose of anti-histamine
13. Currently taking long term asthma maintenance medications – corticosteroids, and leukotriene modifiers that you could not refrain from taking for 4 days prior to laboratory session

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary function data (forced expiratory volume in 1 second, forced vital capacity, and peak expiratory flow) at baseline and in response to the eucapnic voluntary hyperpnoea test (in both asthmatic and non-asthmatic groups).<br><br>Data was collected at day 0 and day 21.

Secondary Outcome Measures

Name	Time	Method
1. Baseline and post eucapnic voluntary hyperpnoea (EVH) blood sampling for markers of airway inflammation (chemokines CCL11 and CCL17; tumour necrosis factor-alpha (TNF-a); c-reactive protein; and immunoglobulin E) – (collected in both asthmatic and non-asthmatic groups)<br>2. Fraction of exhaled nitric oxide (collected in asthmatic group only)<br><br>Serum chemokine and TNF-a levels were measured from blood samples taken at baseline and 15 min, 60 min and 24 h after EVH.<br><br>Data was collected at day 0 and day 21.